Nathan Hunkapiller
Overview
Explore the profile of Nathan Hunkapiller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bar J, Esteban E, Rodriguez-Abreu D, Aix S, Szalai Z, Felip E, et al.
Lung Cancer
. 2024 Feb;
190:107506.
PMID: 38422883
Background: First-line pembrolizumab plus chemotherapy has shown clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC) regardless of tissue tumor mutational burden (tTMB) status. Blood tumor mutational burden...
2.
Alexander G, Lin W, Ortega F, Ramaiah M, Jung B, Ji L, et al.
PLoS One
. 2023 Apr;
18(4):e0283001.
PMID: 37058491
The analytical validation is reported for a targeted methylation-based cell-free DNA multi-cancer early detection test designed to detect cancer and predict the cancer signal origin (tissue of origin). A machine-learning...
3.
Jamshidi A, Liu M, Klein E, Venn O, Hubbell E, Beausang J, et al.
Cancer Cell
. 2022 Nov;
40(12):1537-1549.e12.
PMID: 36400018
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining clinical limit of detection...
4.
Merino Vega D, Nishimura K, Zariffa N, Thompson J, Hoering A, Cilento V, et al.
JCO Precis Oncol
. 2022 Aug;
6:e2100372.
PMID: 35952319
Purpose: As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in...
5.
Ravi H, McNeill G, Goel S, Meltzer S, Hunkapiller N, Ryan A, et al.
PLoS One
. 2018 Feb;
13(2):e0193476.
PMID: 29474437
Introduction: Non-invasive prenatal testing (NIPT) for aneuploidy using cell-free DNA in maternal plasma has been widely adopted. Recently, NIPT coverage has expanded to detect subchromosomal abnormalities including the 22q11.2 deletion....
6.
Ryan A, Hunkapiller N, Banjevic M, Vankayalapati N, Fong N, Jinnett K, et al.
Fetal Diagn Ther
. 2016 Mar;
40(3):219-223.
PMID: 27028530
Objective: To validate an updated version (Version 2) of a single-nucleotide polymorphism (SNP)-based noninvasive prenatal test (NIPT) and to determine the likelihood of success when testing for fetal aneuploidies following...
7.
Pergament E, Cuckle H, Zimmermann B, Banjevic M, Sigurjonsson S, Ryan A, et al.
Obstet Gynecol
. 2014 Jul;
124(2 Pt 1):210-218.
PMID: 25004354
Objective: To estimate performance of a single-nucleotide polymorphism-based noninvasive prenatal screen for fetal aneuploidy in high-risk and low-risk populations on single venopuncture. Methods: One thousand sixty-four maternal blood samples from...
8.
Seumois G, Vijayanand P, Eisley C, Omran N, Kalinke L, North M, et al.
Am J Clin Exp Immunol
. 2013 Jan;
1(2):70-89.
PMID: 23304658
Profiling miRNA expression in cells that directly contribute to human disease pathogenesis is likely to aid the discovery of novel drug targets and biomarkers. However, tissue heterogeneity and the limited...
9.
Moltzahn F, Hunkapiller N, Mir A, Imbar T, Blelloch R
J Vis Exp
. 2011 Aug;
(54).
PMID: 21847076
The broad involvement of miRNAs in critical processes underlying development, tissue homoeostasis and disease has led to a surging interest among the research and pharmaceutical communities. To study miRNAs, it...